Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01158950
Other study ID # 2009-12-461
Secondary ID W81XWH-10-1-0231
Status Completed
Phase N/A
First received
Last updated
Start date March 2010
Est. completion date December 2018

Study information

Verified date November 2020
Source University of California, San Francisco
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study, we seek to understand the effects of tolcapone, an FDA-approved COMT inhibitor, on reward choice and response inhibition, two measures we have previously shown to be altered in subjects with alcoholism. We now plan to test the hypothesis that COMT regulation of cortical dopamine levels is critical for regulation financial choices. Specifically, we propose that the lower levels of cortical dopamine present in individuals with the val158val COMT genotype reduces the inhibitory effect of frontal cortical areas on impulsive choice; an idea that extends previous hypotheses about the negative consequences of decreased prefrontal dopamine levels on inhibitory control. Moreover, this hypothesis suggests that inhibiting COMT may slow the degradation of dopamine and thereby decrease impulsivity.


Description:

Drug consumption despite adverse consequences is a defining feature of human addiction (DSM-IV-TR, 2004). Impulsivity, a tendency to choose an immediate action despite delayed adverse consequences, is a major risk factor for tobacco, psychostimulant, opioid and alcohol abuse. In humans, impulsivity can be quantified by presenting subjects with a choice between a small immediate monetary reward or a larger but delayed reward. We recently found that the val158val allele for the enzyme catechol-O-methyltransferase (COMT), which is associated with more rapid cortical dopamine catabolism and thus lower cortical dopamine levels correlates with greater impulsivity and greater fMRI blood oxygen level dependent (BOLD) signal in dorsolateral prefrontal and posterior parietal cortices. The first phase of the study will involve healthy controls. The second phase of the study will involve abstinent alcoholics matched for age, education, and gender. Subjects will range in age between 18 and 50 years old.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date December 2018
Est. primary completion date December 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - Age between 18 and 50 years. - Subject is right-handed. - If female, subject is non-lactating, not pregnant, and using a reliable contraception method (i.e. abstinence, intrauterine device (IUD), hormonal birth control or barrier method). - Subject is able to read and speak English. - Subject is a high school graduate. - Subject is able and willing to provide written and informed consent. - Subject is able to understand and follow the instructions of the investigator, and understand all ratings scales. - Subject is in good health. Exclusion Criteria: - Using cocaine, stimulants (other than THC, nicotine, & caffeine)amphetamines, hallucinogens, "ecstasy", opiates, sedatives, pain pills, sleeping pills or other psychoactive drugs within two weeks of the start of the study OR more than 10 times in the last year. - Has a current dependence on, or addiction to any psychoactive drug (except nicotine or caffeine) including alcohol. - Clinically significant medical or psychiatric illness requiring treatment as determined by screening blood tests, medical history, and physical exam performed or reviewed by the study physician. - Subject has a history of major alcohol related complications within the proceeding 2 years (liver failure/cirrhosis, pancreatitis, esophageal varices, etc.) - Liver function test = 3 times normal upper limit. - BAC level > 0.05% at the beginning of screening visit (within margin of error of detection). - Has a neurological dysfunction or psychiatric disorder. - Has severe low blood pressure. - Has uncontrolled high blood pressure. - Regular use of any of the drugs on the tolcapone or entacapone contraindications list OR within 2 weeks of drug administration. - Regular use of SSRIs. - Has an allergy or intolerance to tolcapone or entacapone. - Subject has received an investigational drug within 30 days of screening visit. - Subject is considered unsuitable for the study in the opinion of the investigator or study physician for any other reason. MRI Exclusion Criteria: - The subject has metal (metal plates, pins, wires or screws, artificial limb, joint replacement or anything that might have been inserted during an operation) in his/her body. - Subject has a pacemaker, defibrillator, stent, or any metal implants related to heart/blood flow problems. - Subject has worked with metals (ie. metallurgy, metal shaving, welding, soldering, etc). - Subject has been wounded with anything metal (bullet, shrapnel or metal filling). - Has ever gotten a piece of metal in the eye. - Has tattoos done with ink containing metal or permanent eyeliner. - Wears color contact lenses. - Has a hearing problem or hearing aid, cochlear implant or past ear surgery. - Has any irremovable dental bridges, dental plates, metal caps or any other non-removable metal in the mouth. - The subject is claustrophobic. - The subject is pregnant. (women only) - Has a IUD. (women only) - Significantly overweight.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tolcapone
Drug: Tolcapone 200mg (single dose) administered at study visit
Other:
Placebo
Placebo (200mg) administered at study visit

Locations

Country Name City State
United States University of California, Berkeley Berkeley California
United States UCSF: Ernest Gallo Clinic and Research Center Emeryville California

Sponsors (3)

Lead Sponsor Collaborator
University of California, San Francisco United States Department of Defense, University of California, Berkeley

Country where clinical trial is conducted

United States, 

References & Publications (1)

Kayser AS, Allen DC, Navarro-Cebrian A, Mitchell JM, Fields HL. Dopamine, corticostriatal connectivity, and intertemporal choice. J Neurosci. 2012 Jul 4;32(27):9402-9. doi: 10.1523/JNEUROSCI.1180-12.2012. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Correlation Between the Difference in ICR (Tolcapone Minus Placebo) and the Difference in Blood Oxygen Level Dependent (BOLD) Signal in the Brain (Tolcapone Minus Placebo) The presented value represents a correlation. The difference in performance on the delay discounting task was calculated as the change in ICR (tolcapone minus placebo). In addition, the difference in BOLD activity throughout the brain was determined (tolcapone minus placebo). 120 minutes after drug ingestion
Primary Correlation Between the Impulsive Choice Ratio and Baseline Impulsivity, as Measured With the Barratt Impulsiveness Scale The presented value represents a correlation. Subjects completed a delay discounting task while functional MRI images were obtained. In this task, subjects made hypothetical choices between a smaller amount of money available sooner, and a larger amount of money available later. Performance on the delay discounting task, as assessed by the impulsive choice ratio, was determined for both the tolcapone and placebo sessions, and the difference between them (tolcapone minus placebo) was calculated. This difference value was then correlated with baseline scores on the Barratt Impulsiveness Scale. 120 minutes after drug ingestion
See also
  Status Clinical Trial Phase
Recruiting NCT03898336 - Eat2beNICE Vitamins and Nutrients as Supplementation for Impulsivity, Irritability, and Compulsivity N/A
Completed NCT03484377 - Cortical Dynamics of Inhibitory Control: A Concurrent tDCS-MEG Study N/A
Terminated NCT03527550 - Cognitive Control Training for Urgency in a Naturalistic Clinical Setting N/A
Recruiting NCT05894980 - How to Reduce Suicidal Thoughts and Impulsivity in Depression N/A
Recruiting NCT03218670 - Your Health in On Click N/A
Not yet recruiting NCT04811807 - Clinical Response of Impulsivity After Brain Stimulation in Parkinson's Disease
Completed NCT02740582 - Effects of Tolcapone on Decision Making and Alcohol Intake in Alcohol Users Phase 2
Not yet recruiting NCT02595164 - Common Decision Making Deficits in Suicidal Behaviors and Eating Disorders N/A
Recruiting NCT04960969 - The Effects of Time-Restricted Eating Model N/A
Not yet recruiting NCT06226467 - Neurobehavioral Affective Control Training N/A
Not yet recruiting NCT03498937 - Effects of tDCS on Impulsiveness Among People Suffering From Borderline Personality Disorder N/A
Completed NCT03200873 - Effects of rTMS on Impulsivity and Empathy N/A
Terminated NCT03838484 - Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia N/A
Completed NCT04290533 - HD-tDCS Over the dACC in High Trait Impulsivity N/A
Completed NCT05031559 - Episodic Future Thinking and Compassion N/A
Recruiting NCT05875181 - Examining the Impact of Transcranial Focused Ultrasound (tFUS) on Reward Neural Circuitry N/A
Not yet recruiting NCT03190681 - Motivation and Methylphenidate Early Phase 1
Completed NCT01805401 - tDCS Applied to the OFC: Effects on Decision-Making and Impulse Control N/A
Completed NCT03006653 - Understanding Daily Fluctuations in Self-Regulation N/A
Active, not recruiting NCT04785677 - Researching Resiliency in Stressful Experiences (RISE) Program for Men Leaving Incarceration N/A